Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
1.270
+0.040 (3.25%)
At close: Aug 21, 2026, 4:00 PM EDT
1.290
+0.020 (1.57%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Actuate Therapeutics Employees
Actuate Therapeutics had 12 employees as of December 31, 2025. The number of employees increased by 2 or 20.00% compared to the previous year.
Employees
12
Change (1Y)
2
Growth (1Y)
20.00%
Revenue / Employee
n/a
Profits / Employee
-$1,704,484
Market Cap
30.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 2 | 20.00% |
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Sep 30, 2024 | 11 | 6 | 120.00% |
| Jun 30, 2024 | 11 | - | - |
| Mar 31, 2024 | 10 | - | - |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Evaxion | 46 |
| BeyondSpring | 44 |
| NextCure | 40 |
| Quince Therapeutics | 38 |
| Kyntra Bio | 34 |
| Lantern Pharma | 16 |
| Genenta Science | 9 |
ACTU News
- 7 days ago - Actuate Therapeutics Quarterly report: Q2 2026 - Filings
- 8 days ago - Actuate Therapeutics Slides: Corporate presentation - Filings
- 22 days ago - Actuate Therapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 2 months ago - Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma - GlobeNewsWire
- 2 months ago - Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Actuate Therapeutics price target lowered to $5 from $6 at Lucid Capital - TheFly
- 3 months ago - Actuate Therapeutics Quarterly report: Q1 2026 - Filings
- 3 months ago - Actuate Therapeutics receives FDA clearance for oral elraglusib study - TheFly